Table 1

Summary of clinical characteristics and outcomes to anti PD-1 immunotherapy of the study cohort (n=71)

Age at diagnosis, median, years56 (32–86)
Age at metastatic disease, median, years60 (33–86)
Gender, n (%)
 Male35 (49.3)
 Female36 (50.7)
Stage at diagnosis, n (%)
 I/II19 (26.8)
 III24 (33.8)
 IV16 (22.5)
 Primary unknown12 (16.9)
Origin of melanoma, n (%)
 Cutaneous51 (71.8)
 Non-cutaneous20 (28.2)
BRAF status, n (%)
 Mutated34 (47.9)
 wt37 (52.1)
Previous systemic therapy for metastatic disease, n (%)
 Yes34 (47.9)
 No37 (52.1)
Stage at metastatic disease*, n (%)
 M1a14 (19.7)
 M1b9 (12.7)
 M1c31 (43.7)
 M1d17 (23.9)
No of metastatic sites*, n (%)
 1–239 (54.9)
>332 (45.1)
PS (ECOG)*, n (%)
 032 (45.1)
 133 (46.5)
 26 (8.4)
LDH, n (%)
 1 xULN35 (49.3)
 2xULN28 (39.4)
 >2xULN7 (9.9)
 Unspecified1 (1.4)
Best response, n (%)
 ORR29 (40.8)
 DCR33 (46.5)
 CR8 (27.6)
 PD38 (53.5)
PFS median, months4
OS median, months11
  • CR, complete response; DCR, disease control rate; ECOG, Eastern Cooperative Oncology Group ; LDH, lactate dehydrogenase; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PS, Performance Status; ULN, upper limit of normal.